MAP7

Across TCGA pan-cancer cohorts, MAP7 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP7 data layer compared with 17 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MAP7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAP7 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

STAD, UCEC, and KIRC are the cancer types where MAP7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.001	0.667	<.001	36	view →
UCEC	DFS	Median	All	0.961	0.618	.013	14	view →
KIRC	OS	Median	All	0.144	0.655	.029	12	view →
PRAD	DFS	Median	All	0.157	0.888	<.001	12	view →
BLCA	DFS	Median	All	1.000	0.608	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAP7–STAD (OS)

Open the STAD breakdown →